Accessibility StatementSkip Navigation Onassis is about to launch a Reg D 506c to raise funds from US accredited investors Dalmore Group's has more than $2B raised by issuers and more than 1,000,000 processed Onassis Holdings Corp.+1-516-620-6794[email protected]www.ananda-labs.bio Logo: https://mma.prnewswire.com/media/2069172/Onassis_Holdings_Corp_Logo.jpg SOURCE Onassis Holdings Corp WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? With over 16 years of experience and deep relationships in multipl ...

Core Insights - Several healthcare and biotech stocks saw significant price movements in after-hours trading on September 12, with notable gains in companies like Penumbra, Check-Cap, Adaptimmune Therapeutics, and NewAmsterdam Pharma, indicating a volatile session for the sector [1] Company Summaries Penumbra Inc. (PEN) - Penumbra's stock closed at $272.73 during regular trading, down by $3.67 or 1.33%, but rebounded to $289.86 in after-hours, gaining 6.28% [2] - The trading range for the day was $271.83 to $280.14, with a volume of 454,478 shares, slightly below its average of 472,087 [3] - The company has a market capitalization of approximately $10.64 billion and a trailing price-to-earnings ratio of 71.96 based on earnings per share of $3.79 [3] - Penumbra raised its full-year 2025 revenue guidance to $1.355 billion - $1.370 billion, reflecting a growth of 13% - 15% over 2024 revenue of $1.195 billion, and projects a 20% - 21% growth in its U.S. thrombectomy segment [5] - The company appointed Shruthi Narayan as its new president, indicating potential strategic shifts [6] Check-Cap Ltd. (CHEK) - Check-Cap's stock surged from $0.7459 to $2.1600 in after-hours trading, marking a gain of 191.22%, driven by a strategic merger announcement [6] - During regular trading, the stock gained 8.09%, closing at $0.7459, with a trading range of $0.6860 to $0.7602 and a volume of 67,178 shares [7] - The merger with MBody AI aims to enhance Check-Cap's colorectal cancer screening capabilities through AI integration [8] Adaptimmune Therapeutics plc (ADAP) - Adaptimmune's stock rose from $0.0560 to $0.0651 in after-hours trading, a gain of 16.25%, following a 10.89% increase during regular hours [8] - For Q2 2025, the company reported a net loss of $30.3 million, or $0.02 per share, with total revenue of $13.7 million, primarily from product sales of TECELRA [9] - Adaptimmune entered a definitive agreement to sell certain cell therapies for $55 million upfront, with potential future milestone payments of up to $30 million, allowing it to repay debt and restructure for value maximization [10] NewAmsterdam Pharma Company N.V. (NAMS) - NewAmsterdam's shares rose from $24.19 to $26.18 in after-hours trading, an 8.23% gain, following a 9.06% decline during the day [11] - The stock's recovery is attributed to optimism surrounding its lead candidate, obicetrapib, which has received regulatory review acceptance from the EMA [11] - The company reported Q2 2025 revenue of $16.45 million and a net loss of $14.92 million, improving from a $0.41 loss per share in the same quarter of 2024 [13]

Core Viewpoint - The healthcare sector, particularly dividend-paying stocks like Amgen and Merck, presents solid investment opportunities due to their non-cyclical nature and consistent revenue generation even in challenging economic conditions [1][2]. Group 1: Amgen - Amgen is a leading biotech company with a diverse portfolio of over two dozen products, many of which are blockbuster drugs generating over $1 billion in annual sales [4]. - The company reported a 9% year-over-year revenue growth in Q2, reaching $9.2 billion, with non-GAAP earnings per share at $6.02, a 21% increase from the previous year [6]. - Amgen faces patent cliffs and biosimilar competition but has strong growth drivers, including Tezspire for asthma, which saw a 46% year-over-year sales increase to $342 million [7][8]. - The company has a robust dividend profile with a forward yield of 3.4%, having increased its payouts annually since 2011 [9]. Group 2: Merck - Merck is experiencing increased competition for its cancer drug Keytruda, with patent exclusivity expiring in 2028, and has faced declining sales in its vaccine franchise due to paused shipments in China [10][11]. - In Q2, Merck's revenue declined by 2% year-over-year to $15.8 billion [11]. - The company is developing a subcutaneous version of Keytruda to extend its patent life and has received approval for new products like Winrevair for pulmonary arterial hypertension [12][13]. - Merck's forward yield is currently at 3.9%, with an 88.8% increase in dividends over the past decade, making it an attractive option for dividend investors despite current challenges [15].

Group 1 - Avidity Biosciences Inc. (NASDAQ:RNA) experienced a significant stock performance increase, closing up 9.02% at $44.74 after a four-day losing streak, driven by a higher price target and rating from analysts [1][3] - BofA Securities issued a "buy" recommendation for Avidity Biosciences with a new price target of $65, up from $56, indicating a potential upside of 45% from the latest closing price [2] - The investment firm suggested that the current price weakness of Avidity's stock presents a significant opportunity for investors to acquire shares [3] Group 2 - Avidity Biosciences announced a $500 million share sale to fund three late-stage clinical trials, support commercial inventory for upcoming launches, and expand its commercial infrastructure and AOC platform [4] - The company has provided its underwriters with an overallotment option of up to $75 million within 30 days from the offering date [4] - There is uncertainty regarding the completion, size, or terms of the offering, as noted by the company [5]

Core Viewpoint - BioNxt Solutions Inc. has entered into a debt settlement agreement to address an outstanding debt of CAD$225,010 through the issuance of common shares and a cash payment [1] Debt Settlement Details - The total outstanding debt amounts to CAD$225,010 owed for services provided by the creditor [1] - The company will issue 112,505 common shares at a deemed price of CAD$1.00 per share as part of the debt settlement [1] - Additionally, a cash payment of CAD$112,505 will be made to the creditor [1]

Group 1 - The market rally continues with major indexes reaching new records, with several stocks in the IBD 50 list of growth names extended [1] - There are over 15 healthcare names in the IBD 50 list, indicating strong performance in this sector [1] - Stocks that have formed bases may experience significant gains upon breakouts, particularly in the artificial intelligence and software sectors [1] Group 2 - Biotech stocks Zai Labs and BeOne Medicines experienced a significant decline due to rumors of an impending executive order from President Trump [2] - Hims & Hers has seen a remarkable 1,600% increase in share price over less than four years, driven by personalized health products [4] - Travere Therapeutics has shown strong price performance, achieving a three-year high and a rising RS rating of 92 [4]

Company Overview - Biogen Inc. has a market cap of $21.8 billion and specializes in therapies for neurological and neurodegenerative diseases, including multiple sclerosis and spinal muscular atrophy treatments [1] - The company is classified as a "large-cap" stock, valued at $10 billion or more, and is advancing treatments in Alzheimer's disease and other neurological disorders through strategic collaborations and innovation [2] Stock Performance - Biogen's shares have declined 28.3% from its 52-week high of $204.18, while the stock has risen nearly 11% over the past three months, underperforming the Nasdaq Composite's 12.6% increase [3] - Year-to-date, BIIB stock is down nearly 4%, lagging behind the Nasdaq's 14.7% gain, and has decreased 25.8% over the past 52 weeks compared to the Nasdaq's over 26% return [4] Financial Results - On July 31, Biogen reported Q2 2025 adjusted EPS of $5.47 and revenues of $2.65 billion, both exceeding expectations, driven by stronger sales of MS drugs like Vumerity and Tysabri [5] - Management raised its full-year adjusted EPS guidance to $15.50 - $16, indicating a more optimistic outlook for 2025 [5] Analyst Sentiment - Despite the stock's underperformance, analysts maintain a moderately optimistic view on Biogen, with a consensus rating of "Moderate Buy" from 34 analysts and a mean price target of $170.24, representing a 16.5% premium to current levels [6]

Industry Overview - Inhibrx Biosciences, Inc. operates in the competitive biotechnology sector, focusing on protein-based therapeutics for cancer and serious diseases, alongside competitors like Keros Therapeutics, Kymera Therapeutics, iTeos Therapeutics, Harmony Biosciences Holdings, and Vaxcyte [1] Financial Analysis of Inhibrx Biosciences - The company's Return on Invested Capital (ROIC) is -95.25%, significantly lower than its Weighted Average Cost of Capital (WACC) of 8.16%, indicating insufficient returns to cover capital costs [2] - The ROIC to WACC ratio of -11.67 highlights inefficiencies in capital utilization [2] Comparison with Competitors - Keros Therapeutics has a ROIC of 0.03% and a WACC of 8.47%, resulting in a ROIC to WACC ratio of 0.0035, indicating minimal efficiency [3] - Kymera Therapeutics and iTeos Therapeutics report negative ROICs of -29.50% and -42.54%, respectively, with ROIC to WACC ratios of -2.17 and -4.03, reflecting challenges in generating adequate returns [3] - Harmony Biosciences Holdings stands out with a ROIC of 21.25% and a WACC of 7.65%, leading to a ROIC to WACC ratio of 2.78, indicating effective capital utilization [4] - Vaxcyte shows a ROIC of -22.46% and a WACC of 8.40%, with a ROIC to WACC ratio of -2.67, further illustrating inefficiencies in capital utilization [5] Summary of Financial Health - The analysis reveals varying degrees of financial health and capital efficiency among biotechnology companies, with Inhibrx Biosciences facing significant challenges in generating returns that cover its cost of capital [5]

Company Overview - Curis is at an exciting crossroads with a focus on one primary drug, an IRAK4 and FLT3 inhibitor, which is being developed for Non-Hodgkin Lymphoma (NHL) and Acute Myeloid Leukemia (AML) [3] - The company has a promising pipeline and is funding studies for solid tumors, primarily supported by the NIH [3] Drug Development - The drug has shown compelling proof-of-concept data in Primary Central Nervous System Lymphoma (PCNSL) with a study involving 34 patients [3] - The drug is designed to be an add-on therapy to BTK inhibitors, targeting the TLR pathway while BTK inhibitors block the BCR pathway, potentially leading to higher response rates and complete remission in NHL [4]

Core Viewpoint - FibroBiologics presents fibroblast cells as a superior alternative to stem cells for chronic disease therapies, highlighting their therapeutic advantages and potential to transform treatment outcomes [1][2][3]. Company Overview - FibroBiologics is a clinical-stage biotechnology company based in Houston, focusing on developing therapeutics and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials [5][6]. - The company holds over 270 patents issued and pending, covering various clinical pathways including wound healing, multiple sclerosis, and cancer [5][6]. Research and Findings - The editorial authored by company leadership reviews extensive research indicating that fibroblast cells have faster proliferation rates, better sourcing capabilities, and enhanced immune modulation properties compared to stem cells [2][3]. - The evidence suggests that fibroblasts may not only match but potentially exceed the efficacy of mesenchymal stem cells in clinical applications [3]. Future Implications - The leadership at FibroBiologics believes that the transition from stem cell therapies to fibroblast-based solutions represents a paradigm shift in medicine, aiming for long-term improvements in patient outcomes [3]. - The company emphasizes the scalability and effectiveness of fibroblast therapies, which could fundamentally change how chronic diseases are treated [3].